C5 and meningococcal infection: The currently approved C5-neutralizing mAb eculizumab has demonstrated clinical benefits in rare diseases.35 However, owing to the potential increased risk of Neisseria meningitidis infection associated with eculizumab, current evidence lacks large-scale randomized controlled trials (RCTs) to support its routine use in sepsis treatment.36